Ortec to be Granted European Patent on its Fibrin Microbead Enabling Technology
Complete the form below to unlock access to ALL audio articles.
Ortec International, Inc. has announced that it was notified by the European Patent and Trademark Office that the claims of its patent application, "Fibrin Microbeads and uses thereof," have been allowed.
Five U.S. patents relating to the Fibrin Microbead technology (Fibrin MB) have previously been granted.
Commenting on the patent, Ron Lipstein, Ortec's Vice Chairman and CEO, said, "The allowance of the patent claims by the European Patent office underscores the uniqueness of the Fibrin Microbead technology and its role in stem cell therapy."
"The allowance of the claims, which paves the way for the potential issuance of multiple patents throughout Europe, is another value- enhancing milestone toward the development and commercialization of this technology."
The Fibrin Microbead technology developed at Hapto Biotech, Israel, Ortec's wholly owned subsidiary, is a proprietary matrix for the isolation, expansion and differentiation of matrix-dependent cells including Mesenchymal- type adult stems cells and their potential reimplantation into the patient.
